

GENESYS BIOTECH LTD

**Company Registration Number:
04603049 (England and Wales)**

Unaudited abridged accounts for the year ended 31 March 2022

Period of accounts

Start date: 01 April 2021

End date: 31 March 2022

GENESYS BIOTECH LTD

Contents of the Financial Statements for the Period Ended 31 March 2022

Balance sheet

Notes

GENESYS BIOTECH LTD

Balance sheet

As at 31 March 2022

	<i>Notes</i>	2022	2021
		£	£
Fixed assets			
Tangible assets:	3	445,937	497,662
Total fixed assets:		<u>445,937</u>	<u>497,662</u>
Current assets			
Stocks:		262,296	328,657
Debtors:		1,819,437	17,833,829
Cash at bank and in hand:		31,378,146	28,889,634
Total current assets:		<u>33,459,879</u>	<u>47,052,120</u>
Creditors: amounts falling due within one year:		(1,730,595)	(15,165,659)
Net current assets (liabilities):		<u>31,729,284</u>	<u>31,886,461</u>
Total assets less current liabilities:		32,175,221	32,384,123
Total net assets (liabilities):		<u>32,175,221</u>	<u>32,384,123</u>
Capital and reserves			
Called up share capital:		17	17
Other reserves:		10	8
Profit and loss account:		32,175,194	32,384,098
Shareholders funds:		<u>32,175,221</u>	<u>32,384,123</u>

The notes form part of these financial statements

GENESYS BIOTECH LTD

Balance sheet statements

For the year ending 31 March 2022 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 28 February 2023
and signed on behalf of the board by:**

Name: Dr Duncan Roy Clark
Status: Director

The notes form part of these financial statements

GENESYS BIOTECH LTD

Notes to the Financial Statements

for the Period Ended 31 March 2022

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

GENESYS BIOTECH LTD

Notes to the Financial Statements for the Period Ended 31 March 2022

2. Employees

	<i>2022</i>	<i>2021</i>
Average number of employees during the period	10	10

GENESYS BIOTECH LTD

Notes to the Financial Statements for the Period Ended 31 March 2022

3. Tangible Assets

	Total
Cost	£
At 01 April 2021	987,604
Additions	86,402
At 31 March 2022	<u>1,074,006</u>
Depreciation	
At 01 April 2021	489,942
Charge for year	138,127
At 31 March 2022	<u>628,069</u>
Net book value	
At 31 March 2022	<u><u>445,937</u></u>
At 31 March 2021	<u><u>497,662</u></u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.